Delving into the Latest Updates on Leading Biopharm Ltd with Synapse

Overview

主要目的评价TJ301在活动性溃疡性结肠炎（UC）患者中的安全性和有效性次要目的研究TJ301在活动性溃疡性结肠炎患者中的药代动力学研究TJ301在活动性溃疡性结肠炎患者中的药效学研究TJ301在活动性溃疡性结肠炎患者中的免疫原性探索性目的探索TJ301在活动性溃疡性结肠炎患者中的药代动力学和药效学关系

[Translation]

Primary Objective To evaluate the safety and efficacy of TJ301 in patients with active ulcerative colitis (UC) Secondary Objective To study the pharmacokinetics of TJ301 in patients with active UC To study the pharmacodynamics of TJ301 in patients with active UC To study the immunogenicity of TJ301 in patients with active UC Exploratory Objective To explore the pharmacokinetic and pharmacodynamic relationship of TJ301 in patients with active UC

Start Date13 Sep 2018

Sponsor / Collaborator

I-MAB Biopharma (Shanghai) Co., Ltd.

[+2]

100 Clinical Results associated with Leading Biopharm Ltd

Login to view more data

0 Patents (Medical) associated with Leading Biopharm Ltd

Login to view more data

100 Deals associated with Leading Biopharm Ltd

Login to view more data

100 Translational Medicine associated with Leading Biopharm Ltd

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 26 Nov 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Other

1

Login to view more data